21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
18:24 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

AnaptysBio reports Phase IIa data for peanut allergy candidate

AnaptysBio Inc. (NASDAQ:ANAB) reported interim data from a Phase IIa trial showing that six of 13 (46%) patients exhibiting moderate to severe peanut allergy symptoms during a baseline oral food challenge improved their peanut tolerance...
23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
18:01 , Oct 20, 2017 |  BC Week In Review  |  Financial News

AnaptysBio raises $205.5M in follow-on

AnaptysBio Inc. (NASDAQ:ANAB) raised $205.5 million through the sale of 3 million shares at $68.50 in a follow-on underwritten by Credit Suisse, Jefferies, Stifel, Wedbush, Baird and SunTrust. The price is a 3% discount to...
20:58 , Oct 13, 2017 |  BC Extra  |  Financial News

AnaptysBio raises $205.5M in follow-on

AnaptysBio Inc. (NASDAQ:ANAB) raised $205.5 million through the sale of 3 million shares at $68.50 in a follow-on underwritten by Credit Suisse, Jefferies, Stifel, Wedbush, Baird and SunTrust. The price is a 3% discount to...
19:47 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

AnaptysBio's ANB020 meets objective in Phase IIa for atopic dermatitis

AnaptysBio Inc. (NASDAQ:ANAB) said lead program ANB020, an antibody against IL-33, “achieved the trial protocol objective” in a Phase IIa trial to treat moderate to severe atopic dermatitis. The company said the trial had no...
22:18 , Oct 10, 2017 |  BC Extra  |  Clinical News

AnaptysBio shares double on atopic dermatitis data

AnaptysBio Inc. (NASDAQ:ANAB) gained $35.41 (101%) to $70.41 on Tuesday after reporting data from a Phase IIa trial of lead program ANB020, an antibody against IL-33, to treat atopic dermatitis. An AnaptysBio spokesperson told BioCentury...
00:19 , Jan 27, 2017 |  BC Extra  |  Financial News

AnaptysBio raises $75M in upsized IPO

AnaptysBio Inc. (NASDAQ:ANAB) gained $2 to $17 in its first day of trading Thursday after raising $75 million through the sale of 5 million shares at $15 in an IPO underwritten by Credit Suisse, Stifel,...
19:37 , Dec 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Dermatitis Mouse studies suggest inhibiting signaling between IL-33 and IL1RL1 could help treat poison ivy-induced allergic dermatitis. A mouse model of poison ivy-induced dermatitis had high levels of IL-33 in the skin. In the model,...